kc-1438

NIH/3T3-KRAS-WT Cell Line

×
22139
Home » NIH/3T3-KRAS-WT Cell Line

Background of NIH/3T3-KRAS-WT Cell Line

KRAS encodes KRas proto-oncogene, GTPase and is also known as NS. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.

Specifications

Catalog Numberkc-1438
Cell Line NameNIH/3T3-KRAS-WT Cell Line
NCBI/UniProt Accession NumberNM_033360.3
Host Cell LineNIH/3T3
DescriptionNIH/3T3-KRAS-WT is a stable engineered cell line expressing human KRAS-WT
QuantityOne vial of frozen cells (≥2×10⁶ cells/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% DMEM+20% FBS+10% DMSO
Propagation MediumDMEM+10%FBS+1μg/mL Puromycin
Selection MarkerPuromycin
MorphologyEpithelial
SubcultureSplit at a ratio of 1:4–1:6 every 2–3 days
Incubation37 °C with 5% CO₂
StorageLiquid nitrogen immediately upon receiving
Doubling TimeEstimated 19–36 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

NIH/3T3-KRAS-WT cell line was generated using a lentiviral vector expressing the human KRAS-WT sequence.

Characterization

Figure 1: Characterization of NIH/3T3-KRAS-WT Cell Line stable clone using WB.

Figure 2: Characterization of NIH/3T3-KRAS-WT Cell Lines stable clone using PCR.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO₂ incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4–1:6 every 2–3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the pellet in chilled freezing medium, ensuring a minimum cell density of 3×10⁶ cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

  1. Wang H, Chen H, Li S et al. Molecular Mechanisms and Therapeutic Advances in KRAS G12C-Mutant Non-Small Cell Lung Cancer: Toward Mechanism-Guided Longitudinal Management. Cancer innovation. 2026 Oct;5(5):e70082. PMID: 42890422. doi: 10.1002/cai2.70082.
  2. Hao S, Niu T, Wu X et al. Advances in KRAS(G12D)-targeted therapy: from small-molecule inhibitors to PROTACs and molecular glues. Bioorganic chemistry. 2026 Oct 8;183:110633. PMID: 42854602. doi: 10.1016/j.bioorg.2026.110633.
  3. Cai J, Wu Y, Jia X et al. KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine. MedComm. 2026 Oct;7(10):e71050. PMID: 42840361. doi: 10.1002/mco2.71050.

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.